Starlake Bioscience Co Inc Zhaoqing Guangdong

Starlake Bioscience has released its 2026 interim report. Affected by lower selling prices for its main products, net profit attributable to shareholders of the listed company fell by more than 90% year on year in the first half. The financial report shows that in the first half of 2026, the company achieved operating revenue of 8.189 billion yuan, up 0.36% year on year. Net profit attributable to shareholders of the listed company was 70.72 million yuan, down 91.54% year on year. Non-GAAP net profit was 55.28 million yuan, down 93.14% from the same period last year. The company's operating cash flow swung from 614 million yuan in the same period last year to negative 791 million yuan, a year-on-year decrease of 228.82%, mainly because of increased purchases of raw materials during the period. Starlake Bioscience said the main reason for the decline in performance was that, affected by market supply and demand, selling prices for its main products such as monosodium glutamate and amino acids fell, causing overall profit to decline year on year.

Xinghu Technology disclosed its earnings forecast, expecting attributable net profit for the first half of 2026 to be between 60 million and 85 million yuan, a year-on-year decline of 89.84% to 92.83%. Deducted non-recurring net profit is expected to be between 43 million and 60 million yuan, a year-on-year decline of 92.55% to 94.66%. The company primarily focuses on the research, development, production, and sales of food additives, feed additives, and pharmaceutical intermediates and active pharmaceutical ingredients. The change in performance is mainly affected by market supply and demand dynamics, with sales prices of major products declining, leading to reduced product gross margins and an overall year-on-year decline in profit.